Business
Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology
- Exclusive rights to innovative peptide technology positions Ionis to further strengthen targeting capabilities of its LICA therapies CARLSBAD, Calif., July
About this update from Ionis Pharmaceuticals, Inc.
[{"type":"text","content":"- Exclusive rights to innovative peptide technology positions Ionis to further strengthen targeting capabilities of its LICA therapies\n\n\nCARLSBAD, Calif., July 13, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (NASDAQ: BCYC) to increase the delivery capabilities of Ionis' advanced LIgand Conjugated Antisense (LICA) medicines. The agreement provides Ionis exclusive access to Bicycle's proprietary macrocyclic peptides, referred to as Bicycles, to design LICAs that target transferrin receptor 1 for use with oligonucleotides. This LICA strategy has demonstrated both the improved delivery of antisense medicines to muscle tissue, including cardiac muscle, as well as the potential to cross the blood brain barrier.\n\n \n \n \n \n \n \n\n \nBicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development.\n\"One of our key strategic objectives is to expand our drug discovery capabilities. The agreement with Bicycle Therapeutics represents a strategic addition to our expanding LICA platform, giving us the potential to meaningfully expand our drug discovery capabilities and deliver many more transformational medicines to the market,\" said Brett P. Monia, Ph.D., Ionis' chief executive officer. \"We believe that investing in technologies like Bicycle's cutting-edge transferrin receptor 1-targeting peptides will enhance our ability to design medicines to tackle devastating diseases in need of better treatment options.\" \n\"Our collaboration with Bicycle will accelerate Ionis' progress toward creating best-in-class, low molecular weight ligands for muscle-specific targeted delivery,\" said Eric E. Swayze, Ph.D., executive vice president of research at Ionis. \"This approach offers several potential advantages over related strategies in development, including increased potency, more convenient administration, less complex manufactu...